{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:28:18Z","timestamp":1785522498504,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lung adenocarcinoma (LUAD), the predominant histological subtype of non-small cell lung cancer, remains a leading cause of cancer-related mortality worldwide. The RAS signaling pathway plays a critical role in LUAD pathogenesis; however, the heterogeneity of RAS pathway activity and its clinical implications remain poorly understood. This study aimed to characterize RAS pathway activity subtypes and develop a robust prognostic model for LUAD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Transcriptomic data from 624 LUAD patients (GEO datasets: GSE31210 and GSE72094) were analyzed as the training cohort, with TCGA-LUAD as validation. Consensus clustering stratified patients based on 238 RAS pathway-related genes. Candidate genes were identified through differential expression analysis and WGCNA. Machine learning algorithms (LASSO, Random Forest, SHAP) were applied to construct a prognostic risk model. Comprehensive analyses including GSEA, CIBERSORTx-based immune infiltration, ESTIMATE scoring, and drug sensitivity prediction were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study identified two distinct RAS pathway activity subtypes among LUAD patients. A three-gene prognostic signature (MAPK10, PLA2G12B, SHC3) was established, with the risk score serving as an independent prognostic indicator. Risk score was an independent prognostic factor. Immune landscape analysis demonstrated that high- and low-risk patients showed different expression levels of immune cells. All signature genes correlated positively with resting mast cells, while MAPK10 and PLA2G12B negatively correlated with activated CD4\u2009+\u2009memory T cells. GSEA revealed high-risk tumors enriched in DNA replication, cell cycle, and base excision repair, whereas low-risk tumors favored drug and retinol metabolism pathways. Low-risk patients exhibited lower TIDE and exclusion scores, indicating better immunotherapy response potential. Eight therapeutic compounds (genistein, metformin, quercetin, JNK-9\u00a0L) demonstrated favorable binding to signature genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study established a comprehensive landscape of RAS pathway activity subtypes in LUAD, identifying MAPK10, PLA2G12B, and SHC3 as novel prognostic biomarkers with significant associations with immune microenvironment remodeling, providing new insights for personalized treatment strategies and therapeutic target development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12672-026-05282-9","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T13:12:34Z","timestamp":1779973954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["RAS pathway activity subtypes identified by machine learning define prognostic and immune microenvironment characteristics in lung adenocarcinoma"],"prefix":"10.1007","volume":"17","author":[{"given":"Yao","family":"shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"4","key":"5282_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40265-014-0182-z","volume":"74","author":"B Piperdi","year":"2014","unstructured":"Piperdi B, Merla A, Perez-Soler R. Targeting angiogenesis in squamous non-small cell lung cancer. Drugs. 2014;74(4):403\u201313.","journal-title":"Drugs"},{"key":"5282_CR2","doi-asserted-by":"publisher","first-page":"1201573","DOI":"10.3389\/fimmu.2023.1201573","volume":"14","author":"Q Ren","year":"2023","unstructured":"Ren Q, Zhang P, Lin H, Feng Y, Chi H, Zhang X, Xia Z, Cai H, Yu Y. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts. Front Immunol. 2023;14:1201573.","journal-title":"Front Immunol"},{"issue":"14","key":"5282_CR3","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The Frequency of Ras Mutations in Cancer. Cancer Res. 2020;80(14):2969\u201374.","journal-title":"Cancer Res"},{"issue":"2","key":"5282_CR4","doi-asserted-by":"publisher","first-page":"118570","DOI":"10.1016\/j.bbamcr.2019.118570","volume":"1867","author":"I Khan","year":"2020","unstructured":"Khan I, Rhett JM, O\u2019Bryan JP. Therapeutic targeting of RAS: New hope for drugging the undruggable. Biochim Biophys Acta Mol Cell Res. 2020;1867(2):118570.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"6","key":"5282_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jtho.2022.02.013","volume":"17","author":"D Jain","year":"2022","unstructured":"Jain D, Nambirajan A, Chen G, Geisinger K, Hiroshima K, Layfield L, Minami Y, Moreira AL, Motoi N, Papotti M, et al. NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. J Thorac Oncol. 2022;17(6):793\u2013805.","journal-title":"J Thorac Oncol"},{"key":"5282_CR6","doi-asserted-by":"publisher","first-page":"101106","DOI":"10.1016\/j.currproblcancer.2024.101106","volume":"51","author":"E Harris","year":"2024","unstructured":"Harris E, Thawani R. Current perspectives of KRAS in non-small cell lung cancer. Curr Probl Cancer. 2024;51:101106.","journal-title":"Curr Probl Cancer"},{"issue":"2","key":"5282_CR7","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1158\/2159-8290.CD-23-0289","volume":"14","author":"Z Li","year":"2024","unstructured":"Li Z, Zhuang X, Pan CH, Yan Y, Thummalapalli R, Hallin J, Torborg S, Singhal A, Chang JC, Manchado E, et al. Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma. Cancer Discov. 2024;14(2):308\u201325.","journal-title":"Cancer Discov"},{"issue":"11","key":"5282_CR8","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov. 2014;13(11):828\u201351.","journal-title":"Nat Rev Drug Discov"},{"key":"5282_CR9","doi-asserted-by":"publisher","first-page":"924239","DOI":"10.3389\/fonc.2022.924239","volume":"12","author":"XQ Yin","year":"2022","unstructured":"Yin XQ, Yin XH, Yu YQ, Xu L, Zhang M. Genomic Landscape of RTK\/RAS Pathway and Tumor Immune Infiltration as Prognostic Indicator of Lung Adenocarcinoma. Front Oncol. 2022;12:924239.","journal-title":"Front Oncol"},{"issue":"3","key":"5282_CR10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2023.12.021","volume":"42","author":"L Cords","year":"2024","unstructured":"Cords L, Engler S, Haberecker M, R\u00fcschoff JH, Moch H, de Souza N, Bodenmiller B. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell. 2024;42(3):396\u2013e412395.","journal-title":"Cancer Cell"},{"issue":"6","key":"5282_CR11","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.21147\/j.issn.1000-9604.2025.06.11","volume":"37","author":"P Zhang","year":"2025","unstructured":"Zhang P, Liang X, Ye B, Wang X, Wang Y, Gong Z, Huang Y, Liu J, Huang C, Luo P. Metabolic reprogramming signature predicts immunotherapy efficacy in lung adenocarcinoma: Targeting SLC25A1 to overcome immune resistance. Chin J Cancer Res. 2025;37(6):1000\u201319.","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"5282_CR12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1186\/s12967-023-04486-9","volume":"21","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xie B, Chen Q. RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment. J Transl Med. 2023;21(1):595.","journal-title":"J Transl Med"},{"key":"5282_CR13","doi-asserted-by":"publisher","first-page":"116058","DOI":"10.1016\/j.biopha.2023.116058","volume":"171","author":"M Xu","year":"2024","unstructured":"Xu M, Zhao X, Wen T, Qu X. Unveiling the role of KRAS in tumor immune microenvironment. Biomed Pharmacother. 2024;171:116058.","journal-title":"Biomed Pharmacother"},{"key":"5282_CR14","doi-asserted-by":"publisher","first-page":"105092","DOI":"10.1016\/j.ebiom.2024.105092","volume":"102","author":"J Xu","year":"2024","unstructured":"Xu J, Zhang Y, Li M, Shao Z, Dong Y, Li Q, Bai H, Duan J, Zhong J, Wan R, et al. A single-cell characterised signature integrating heterogeneity and microenvironment of lung adenocarcinoma for prognostic stratification. EBioMedicine. 2024;102:105092.","journal-title":"EBioMedicine"},{"issue":"5","key":"5282_CR15","doi-asserted-by":"publisher","first-page":"697","DOI":"10.32604\/or.2023.029458","volume":"31","author":"X Wang","year":"2023","unstructured":"Wang X, Jiang S, Zhou X, Wang X, Li L, Tang J. Prognostic-related genes for pancreatic cancer typing and immunotherapy response prediction based on single-cell sequencing data and bulk sequencing data. Oncol Res. 2023;31(5):697\u2013714.","journal-title":"Oncol Res"},{"issue":"6","key":"5282_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/1759-7714.13833","volume":"12","author":"L Niu","year":"2021","unstructured":"Niu L, Guo W, Song X, Song X, Xie L. Tumor-educated leukocytes mRNA as a diagnostic biomarker for non-small cell lung cancer. Thorac Cancer. 2021;12(6):737\u201345.","journal-title":"Thorac Cancer"},{"key":"5282_CR17","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1016\/j.csbj.2020.10.007","volume":"18","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Ma Y, Huang Y, Zhang Y, Jiang Q, Zhou M, Su J. Benchmarking algorithms for pathway activity transformation of single-cell RNA-seq data. Comput Struct Biotechnol J. 2020;18:2953\u201361.","journal-title":"Comput Struct Biotechnol J"},{"issue":"4","key":"5282_CR18","doi-asserted-by":"publisher","first-page":"e25571","DOI":"10.1016\/j.heliyon.2024.e25571","volume":"10","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Sun Q, Shen Q, Li X, Qian J. Development and implementation of a prognostic model for clear cell renal cell carcinoma based on heterogeneous TLR4 expression. Heliyon. 2024;10(4):e25571.","journal-title":"Heliyon"},{"key":"5282_CR19","doi-asserted-by":"crossref","unstructured":"Cheng A, Hu G, Li WV. Benchmarking cell-type clustering methods for spatially resolved transcriptomics data. Brief Bioinform 2023, 24(1).","DOI":"10.1093\/bib\/bbac475"},{"issue":"5","key":"5282_CR20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.21147\/j.issn.1000-9604.2025.05.11","volume":"37","author":"W Xia","year":"2025","unstructured":"Xia W, Liu J, Chen R, Feng J, Wu L, Wang Y, Wang X, Song C, Mao W. Molecular subtypes and prognostic signature rooted in disulfidptosis highlight tumor microenvironment in lung adenocarcinoma. Chin J Cancer Res. 2025;37(5):796\u2013820.","journal-title":"Chin J Cancer Res"},{"key":"5282_CR21","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.csbj.2021.01.028","volume":"19","author":"RB Ghannam","year":"2021","unstructured":"Ghannam RB, Techtmann SM. Machine learning applications in microbial ecology, human microbiome studies, and environmental monitoring. Comput Struct Biotechnol J. 2021;19:1092\u2013107.","journal-title":"Comput Struct Biotechnol J"},{"key":"5282_CR22","doi-asserted-by":"crossref","unstructured":"Ikushima H, Usui K. Identification of age-dependent features of human bronchi using explainable artificial intelligence. ERJ Open Res 2023, 9(5).","DOI":"10.1183\/23120541.00362-2023"},{"key":"5282_CR23","doi-asserted-by":"publisher","first-page":"7145","DOI":"10.2147\/IJGM.S334601","volume":"14","author":"B Liu","year":"2021","unstructured":"Liu B, Yang S. A Five Autophagy-Related Long Non-Coding RNA Prognostic Model for Patients with Lung Adenocarcinoma. Int J Gen Med. 2021;14:7145\u201358.","journal-title":"Int J Gen Med"},{"issue":"8","key":"5282_CR24","doi-asserted-by":"publisher","first-page":"e10164","DOI":"10.1016\/j.heliyon.2022.e10164","volume":"8","author":"X Tang","year":"2022","unstructured":"Tang X, Qi C, Zhou H, Liu Y. A novel metabolic-immune related signature predicts prognosis and immunotherapy response in lung adenocarcinoma. Heliyon. 2022;8(8):e10164.","journal-title":"Heliyon"},{"issue":"1","key":"5282_CR25","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1186\/s12967-025-06889-2","volume":"23","author":"H Zhang","year":"2025","unstructured":"Zhang H, Mu Q, Jiang Y, Zhao X, Jia X, Wang K, Li X, Sun D. Integrative single-cell and machine learning approach to characterize immunogenic cell death and tumor microenvironment in LUAD. J Transl Med. 2025;23(1):1000.","journal-title":"J Transl Med"},{"issue":"8","key":"5282_CR26","doi-asserted-by":"publisher","first-page":"793","DOI":"10.4155\/fmc-2018-0468","volume":"11","author":"R Pradhan","year":"2019","unstructured":"Pradhan R, Singhvi G, Dubey SK, Gupta G, Dua K. MAPK Pathway: a Potential Target for the Treatment of Non-small-cell Lung Carcinoma. Future Med Chem. 2019;11(8):793\u20135.","journal-title":"Future Med Chem"},{"key":"5282_CR27","doi-asserted-by":"publisher","first-page":"114452","DOI":"10.1016\/j.biopha.2023.114452","volume":"161","author":"M Alam","year":"2023","unstructured":"Alam M, Hasan GM, Eldin SM, Adnan M, Riaz MB, Islam A, Khan I, Hassan MI. Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma. Biomed Pharmacother. 2023;161:114452.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5282_CR28","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1186\/s40001-025-02807-w","volume":"30","author":"Y Lei","year":"2025","unstructured":"Lei Y, Li X, Fan F, Feng R, He J, Zhong J, Zeng F, Tang Y. ERCC1\/NGFR affects prognosis in basal-like breast cancer. Eur J Med Res. 2025;30(1):597.","journal-title":"Eur J Med Res"},{"key":"5282_CR29","doi-asserted-by":"publisher","first-page":"652081","DOI":"10.3389\/fonc.2021.652081","volume":"11","author":"H Chen","year":"2021","unstructured":"Chen H, Huang J, Chen C, Jiang Y, Feng X, Liao Y, Yang Z. NGFR Increases the Chemosensitivity of Colorectal Cancer Cells by Enhancing the Apoptotic and Autophagic Effects of 5-fluorouracil via the Activation of S100A9. Front Oncol. 2021;11:652081.","journal-title":"Front Oncol"},{"issue":"5\u20136","key":"5282_CR30","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1080\/15384047.2021.1939638","volume":"22","author":"O Maehara","year":"2021","unstructured":"Maehara O, Suda G, Natsuizaka M, Shigesawa T, Kanbe G, Kimura M, Sugiyama M, Mizokami M, Nakai M, Sho T, et al. FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma. Cancer Biol Ther. 2021;22(5\u20136):372\u201380.","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"5282_CR31","doi-asserted-by":"publisher","first-page":"300060524128132","DOI":"10.1177\/03000605241281322","volume":"52","author":"R Zhang","year":"2024","unstructured":"Zhang R, Zhao J, Zhao L. High NTRK2 protein expression levels may be associated with poorer prognosis of breast cancer patients. J Int Med Res. 2024;52(9):3000605241281322.","journal-title":"J Int Med Res"},{"issue":"2","key":"5282_CR32","first-page":"704","volume":"40","author":"Z Yu","year":"2018","unstructured":"Yu Z, Lou L, Zhao Y. Fibroblast growth factor 18 promotes the growth, migration and invasion of MDA\u2013MB\u2013231 cells. Oncol Rep. 2018;40(2):704\u201314.","journal-title":"Oncol Rep"},{"issue":"20","key":"5282_CR33","doi-asserted-by":"publisher","first-page":"7351","DOI":"10.1128\/MCB.22.20.7351-7363.2002","volume":"22","author":"G Pelicci","year":"2002","unstructured":"Pelicci G, Troglio F, Bodini A, Melillo RM, Pettirossi V, Coda L, De Giuseppe A, Santoro M, Pelicci PG. The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase\/Akt signaling pathway. Mol Cell Biol. 2002;22(20):7351\u201363.","journal-title":"Mol Cell Biol"},{"issue":"9","key":"5282_CR34","doi-asserted-by":"publisher","first-page":"10768","DOI":"10.1002\/cam4.5768","volume":"12","author":"Y Liu","year":"2023","unstructured":"Liu Y, Cao F, Xia F, Li J, Dong X, Guo Y, Zhang J, Zhao Q, Liu Y. Shc3 facilitates breast cancer drug resistance by interacting with ErbB2 to initiate ErbB2\/COX2\/MDR1 axis. Cancer Med. 2023;12(9):10768\u201380.","journal-title":"Cancer Med"},{"issue":"6","key":"5282_CR35","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/sj.leu.2404193","volume":"20","author":"J Ying","year":"2006","unstructured":"Ying J, Li H, Cui Y, Wong AH, Langford C, Tao Q. Epigenetic disruption of two proapoptotic genes MAPK10\/JNK3 and PTPN13\/FAP-1 in multiple lymphomas and carcinomas through hypermethylation of a common bidirectional promoter. Leukemia. 2006;20(6):1173\u20135.","journal-title":"Leukemia"},{"issue":"6","key":"5282_CR36","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.21873\/cgp.20552","volume":"22","author":"MN Sulaimani","year":"2025","unstructured":"Sulaimani MN, Singh P, Saeed MU, Zaidi S, Hussain A, Alajmi MF, Shamsi A, Dohare R, Hassan MI. Investigating the Roles of MAPKs as Precision Oncology Targets: A Multi-cancer Expression and Survival Study. Cancer Genomics Proteom. 2025;22(6):1006\u201324.","journal-title":"Cancer Genomics Proteom"},{"key":"5282_CR37","doi-asserted-by":"crossref","unstructured":"Khan SA, Ilies MA. The Phospholipase A2 Superfamily: Structure, Isozymes, Catalysis, Physiologic and Pathologic Roles. Int J Mol Sci 2023, 24(2).","DOI":"10.3390\/ijms24021353"},{"key":"5282_CR38","doi-asserted-by":"crossref","unstructured":"Hidalgo I, Sorolla MA, Sorolla A, Salud A, Parisi E. Secreted Phospholipases A2: Drivers of Inflammation and Cancer. Int J Mol Sci 2024, 25(22).","DOI":"10.3390\/ijms252212408"},{"key":"5282_CR39","doi-asserted-by":"publisher","first-page":"144589","DOI":"10.1016\/j.gene.2020.144589","volume":"742","author":"K Ozturk","year":"2020","unstructured":"Ozturk K, Onal MS, Efiloglu O, Nikerel E, Yildirim A, Telci D. Association of 5\u2019UTR polymorphism of secretory phospholipase A2 group IIA (PLA2G2A) gene with prostate cancer metastasis. Gene. 2020;742:144589.","journal-title":"Gene"},{"issue":"8","key":"5282_CR40","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"5282_CR41","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","volume":"17","author":"L Cassetta","year":"2018","unstructured":"Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887\u2013904.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"5282_CR42","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41571-019-0222-4","volume":"16","author":"ME Shaul","year":"2019","unstructured":"Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16(10):601\u201320.","journal-title":"Nat Rev Clin Oncol"},{"key":"5282_CR43","doi-asserted-by":"publisher","first-page":"1491872","DOI":"10.3389\/fimmu.2024.1491872","volume":"15","author":"H Zhang","year":"2024","unstructured":"Zhang H, Dai J, Mu Q, Zhao X, Lin Z, Wang K, Wang M, Sun D. Macrophage heterogeneity and oncogenic mechanisms in lung adenocarcinoma: insights from scRNA-seq analysis and predictive modeling. Front Immunol. 2024;15:1491872.","journal-title":"Front Immunol"},{"issue":"1","key":"5282_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12967-017-1378-2","volume":"16","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Niu C, Cui J. Gamma-delta (\u03b3\u03b4) T cells: friend or foe in cancer development? J Transl Med. 2018;16(1):3.","journal-title":"J Transl Med"},{"key":"5282_CR45","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3389\/fimmu.2017.00424","volume":"8","author":"G Varricchi","year":"2017","unstructured":"Varricchi G, Galdiero MR, Loffredo S, Marone G, Iannone R, Marone G, Granata F. Are Mast Cells MASTers in Cancer? Front Immunol. 2017;8:424.","journal-title":"Front Immunol"},{"issue":"1","key":"5282_CR46","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12935-022-02677-w","volume":"22","author":"P Asgharian","year":"2022","unstructured":"Asgharian P, Tazekand AP, Hosseini K, Forouhandeh H, Ghasemnejad T, Ranjbar M, Hasan M, Kumar M, Beirami SM, Tarhriz V, et al. Potential mechanisms of quercetin in cancer prevention: focus on cellular and molecular targets. Cancer Cell Int. 2022;22(1):257.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"5282_CR47","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0006-2952(02)00904-8","volume":"63","author":"JM Jamison","year":"2002","unstructured":"Jamison JM, Gilloteaux J, Taper HS, Calderon PB, Summers JL. Autoschizis: a novel cell death. Biochem Pharmacol. 2002;63(10):1773\u201383.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"5282_CR48","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.bcp.2013.11.008","volume":"87","author":"HH Cao","year":"2014","unstructured":"Cao HH, Tse AK, Kwan HY, Yu H, Cheng CY, Su T, Fong WF, Yu ZL. Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling. Biochem Pharmacol. 2014;87(3):424\u201334.","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"5282_CR49","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1016\/j.ajpath.2025.07.017","volume":"195","author":"Y Ding","year":"2025","unstructured":"Ding Y, Zhang H, Wen H, Zhao S, Li J, Liu X, Wang K, Huang Y, Xu M, Sun D. Single-Cell and Spatial Transcriptomics-Based Research Reveals Association Between M2a Macrophages and Tumor Spread through Air Spaces in Lung Adenocarcinoma. Am J Pathol. 2025;195(12):2477\u201391.","journal-title":"Am J Pathol"},{"issue":"3","key":"5282_CR50","first-page":"397","volume":"1","author":"X Ke","year":"2025","unstructured":"Ke X, Li K, Jiang A, Zhang Y, Wang Q, Li Z, Zhang J, Hajd A, Shi W, Kahlert U, et al. Cloud-Based GWAS Platform: An Innovative Solution for Efficient Acquisition and Analysis of Genomic Data. Med Res. 2025;1(3):397\u2013411.","journal-title":"Med Res"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05282-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05282-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05282-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:15:55Z","timestamp":1785518155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05282-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5282"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05282-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study utilized publicly available datasets and did not involve direct human subjects research. Therefore, ethical approval was not required. Not applicable, as this study is based entirely on publicly available transcriptomic datasets.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1085"}}